Cold-Chain-Free Translation of Biomaterials, controlled release, immunoengineering and vaccine delivery: Integrating Formulation, Mucosal Delivery, and Immune Memory

Central issues in vaccination delivery for cold-chain-free biomaterials are discussed in the context of Cold-Chain-Free Translation of Biomaterials, controlled release and vaccine delivery—the focus is on temperature-sensitive antigen, adjuvants and delivery matrices limiting access due to requirement for uninterrupted refrigeration. The more successful development strategy focuses on a quantifiable mechanism, instead of a single 'lit' assay result. Chemistry, biology, exposure, resistance, safety and production become part of one translational argument as a result of this shift.

The scientific basis is a process that involves the simultaneous stabilization of the material with controlled release, targeting to the mucosa with cold-chain free translation and the generation of a long-lasting immune memory in realistic storage conditions. No single measurement can support all of the mechanistic claim, each component provides a separate answer to a separate question. With connected evidence, there's less risk that potency, binding, formulation performance and/or model-fitting might be confused with understanding of the therapeutic action.

Design of vaccines which require no cold chain is more than just thermal stability. Antigens must retain their structure, the ability to react as an adjuvant, and release characteristics following transport and administration in the case of dry powders, lyophilized matrices, dissolving devices and stabilized depots. Mucosal delivery includes proteases, mucus turnover, epithelial barriers and very quick clearance. A warm storage-resistant formulation which produces antigen too rapidly at the mucosa may not go so well with regard to the timing to produce a strong memory.

Joint treatment of design variables is necessary because changes in the performance of a design variable may occur at the same time in the same product as changes in other design variables. The ability to optimize one factor at the expense of other factors is a common disadvantage, particularly when the potency of a given molecule is compromised by its stability, selectivity, delivery or manufacturability. Multiparameter decision rules do result in a more realistic ranking of candidates than with a single numerical endpoint.

Failure routes can also be measured early to gain mechanistic confidence. Protein unfolding, degradation of adjuvents, hydrolysis, particle fusion, change in protein release, clearance by the mucous barrier and local enzymatic degradation with loss of potency are important escape pathways. Stress testing is used to convert the above routes into design data to be used for the next chemistry/ formulation/dosing/ model cycle.

Exposure is the link between nominal dose and impact on the biology. These parameters are: mucosal residence time, epithelial transport, antigen-presenting-cell phagocytosis, lymphoid cell trafficking, antigen release time, and memory-cell stimulation. A candidate that is very active on its own, but performs poorly in the simple assays at the causal site may appear to be very good, but may not be suitable for translation.

Direct interaction or disruption of the functionality must be assessed at realistic concentrations. High doses can give rise to secondary stress responses, to off target effects or to artefacts in the assay that simulate a desired response. Concentration-response relationship combined with exposure and occupancy can be used to determine the range in which the hypothesized causal pathway is likely to take place.

Biological context also influences interpretation in controlled-release vaccines designed to be used in a context where refrigeration, frequent visits to the clinic or an injection is a logistical problem. Target dependence and effective exposure can vary between different genotypes, cell state, tissue architecture, immune tone, metabolic environment and previous treatments. The representative model panels thus offer more evidence than multiple testing in a single system.

Adaptation and/or resistance should be assessed in a prospective fashion, not in a retrospective way. Continued stress such as serial passage, long-term selection, genetic perturbation, repeated dosing or environmental stress can identify those mechanisms that persist under continual pressure. A less powerful candidate, yet with a higher escaping power, may have more 'translation value' than a weak screening leader.

The combination of Safety Assessment with Mechanism provides more information about the safety. Mucosal irritation, local inflammation, foreign-body response, over-activation of innate immune system, systemic exposure and repeat dose tolerability are key concerns. A comparison of desired engagement with unwanted biological responses helps differentiate out between mechanism linked pharmacology and broad cellular injury, or formulation driven toxicity.

Drying cycle, excipient distribution, packaging barrier, fill-finish, device compatibility, moisture protection, shipping resilience – the list of factors that influence the product that is presented to biological systems, goes on and on, and manufacturing cannot be a downstream logistics exercise if it is not designed to perform this critical function. Even with a nominal product name, slight process changes can have an impact on the composition, physical state, level of impurities, product stability, and/or dose reproducibility. Robustness is gained with development if there are direct connections between critical process attributes and mechanistic behavior.

Computational tools provide leverage in the form of speeded up stability modeling, release prediction, design-of-experiments, thermal excursion simulation, and systems-level immune-response mapping. Prediction can be most useful if there is some ambiguity and uncertainty in the response, and where the limits of applicability and uncertainty are still apparent, particularly near novel chemical structures, unusual biological states, or sparse datasets. Decisions about which experiments to select that incorporate uncertainty into models are better than those based on models that provide rankings of experiments with high levels of certainty without providing any indication that the evidence is uncertain.

Thermal challenge, humidity stress, reconstitution/ administer tests, antigenicity, functional protection assays and long term memory measurements are required for prospective validation. Orthogonal tests are important as repeated measurements from a single assay family may generate the same hidden bias, which does not reinforce the causality. When there is consensus between independent methods, this provides greater confidence in the design choice to biological consequence link, and disagreement indicates areas for revising assumptions.

Data integration shall be able to maintain the traceability from raw experiments to development decisions. Chemical structures, analysis metadata from assays, exposure data, omics features, resistance data, and safety signals should be identified and analysed in a versioned manner. Such discipline makes later interpretation from the result to be within the exact conditions that gave rise to the result.

Some of the metrics for making decisions also should be translated, not laboratory show. It is useful to have scorecards that include factors of reproducibility, exposure-normalized activity, mechanistic confidence, resistance frequency, safety margin, stability, and manufacturing robustness. This will encourage candidates who have a balanced approach and will show any compromises before embarking on costly development commitments.

In this context negative results have an unusually high value. I'm in the process of creating a boundary to a hypothesis, and so far, the following elements seem to be responsible for that failure: Failed synthesis, no target engagement, unstable exposure, lack of rescue, emergence of resistance and poor batch reproducibility, loss of activity in realistic models. By recording those failures, experimental design can be improved in future experiments and unnecessary reinvestment of time to support less appealing explanations can be avoided.

Another critical filter, reproducibility across laboratories/batches. Mechanisms that are based on one operator, one preparation, one cell line, or one modeling option are fragile even if it appears that there is a strong statistical significance. Durable biology vs. local success of experiment show independent repetition under exposure matched conditions.

It's also important to have a practical perspective on clinical or deployment conditions when translating. Whether or not there is a realistic value to a product that is technically sophisticated depends on route, administrative burden, diagnostic requirements, storage, monitoring and cost, and timing of treatment. Mechanistic excellence is impactful when the product design is applicable to the environment in which biological benefit is desired.

An additional dimension is added by temporal design, because the response of a biological system to short pulses, sustained exposure, washout and repeated dosing is different. Time-resolved measurements can discriminate between primary engagement and adaptation occurring downstream and show if the early activity remains when the initiating stimuli is removed. Sampling schedules should thus be aligned to the anticipated time course of cold-chain-free biomaterial vaccine delivery, and not be a single endpoint.

An integrated development record helps with better communication throughout the medicinal chemistry, formulation science, pharmacology, computation, manufacturing, and clinical planning aspects of drug development. Rather than providing an absolute history, the record can differentiate known connections, probable assumptions, unanswered questions, and next experiments with the maximum information content. This transparency helps to make iteration quicker and avoid pressure to justify early assumptions when conflicting data comes to light.

It is important to use a credible reference condition for benchmarking to maintain the novelty perspective. New approach is better in predicting, mechanism, durability or manufacturability defined by established compounds which are known inactive, standard formulations, baseline models or accepted analytical methods. Head-to-head comparison also reveals gains that are not observed following exposure normalization, assay sensitivity, batch quality normalization or experimental complexity normalization.

When physical stability preserves the quality of the antigen, and the time required for long duration of immunity, cold-chain-free vaccine engineering is successful. The determining factor is not whether the candidate is successful in one assay, but the proposed mechanism must be valid through exposure, biological, resistance, safety and production. That standard provides a more rigorous track through the discovery signal to a therapeutic concept that can withstand the rigors of reality.